Principal Financial Group Inc Revance Therapeutics, Inc. Transaction History

Principal Financial Group Inc

$172 Billion
Q3 2024

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	SELL	$2.34 - $4.73 $5,824 - $11,772	-2,489 Reduced 11.93%	18,375 $47,000
Q1 2024 Apr 29, 2024	SELL	$4.65 - $9.31 $1.16 Million - $2.32 Million	-248,854 Reduced 92.26%	20,864 $102,000
Q4 2023 Feb 07, 2024	SELL	$5.81 - $11.2 $4.03 Million - $7.77 Million	-693,311 Reduced 71.99%	269,718 $2.37 Million
Q3 2023 Nov 02, 2023	BUY	$11.47 - $25.07 $3.93 Million - $8.59 Million	342,540 Added 55.2%	963,029 $11 Million
Q2 2023 Aug 07, 2023	BUY	$24.7 - $37.61 $14.6 Million - $22.2 Million	589,229 Added 1884.93%	620,489 $15.7 Million
Q1 2023 May 09, 2023	SELL	$18.36 - $35.27 $60,698 - $116,602	-3,306 Reduced 9.56%	31,260 $1.01 Million
Q4 2022 Feb 09, 2023	BUY	$18.32 - $30.66 $292,442 - $489,425	15,963 Added 85.81%	34,566 $638,000
Q3 2022 Nov 09, 2022	SELL	$14.33 - $28.47 $4,155 - $8,256	-290 Reduced 1.53%	18,603 $502,000
Q2 2022 Aug 10, 2022	BUY	$11.52 - $20.4 $69,615 - $123,277	6,043 Added 47.03%	18,893 $261,000
Q1 2022 May 09, 2022	BUY	$12.36 - $20.31 $11,284 - $18,543	913 Added 7.65%	12,850 $251,000
Q4 2021 Feb 09, 2022	SELL	$12.46 - $27.87 $8.62 Million - $19.3 Million	-691,506 Reduced 98.3%	11,937 $195,000
Q3 2021 Nov 09, 2021	BUY	$25.78 - $33.21 $639,653 - $824,006	24,812 Added 3.66%	703,443 $19.6 Million
Q2 2021 Aug 10, 2021	BUY	$26.8 - $31.84 $3.49 Million - $4.15 Million	130,338 Added 23.77%	678,631 $20.1 Million
Q1 2021 May 10, 2021	BUY	$24.03 - $29.97 $2.75 Million - $3.43 Million	114,515 Added 26.4%	548,293 $15.3 Million
Q4 2020 Feb 08, 2021	SELL	$23.41 - $28.34 $3.14 Million - $3.8 Million	-134,067 Reduced 23.61%	433,778 $12.3 Million
Q3 2020 Nov 06, 2020	BUY	$23.23 - $34.3 $71,711 - $105,884	3,087 Added 0.55%	567,845 $14.3 Million
Q2 2020 Aug 05, 2020	BUY	$12.6 - $26.55 $2.04 Million - $4.29 Million	161,601 Added 40.08%	564,758 $13.8 Million
Q1 2020 May 12, 2020	SELL	$12.46 - $27.81 $167,076 - $372,904	-13,409 Reduced 3.22%	403,157 $5.97 Million
Q4 2019 Feb 05, 2020	BUY	$11.66 - $20.15 $1.09 Million - $1.88 Million	93,213 Added 28.83%	416,566 $6.76 Million
Q3 2019 Nov 13, 2019	BUY	$10.22 - $14.5 $1.02 Million - $1.45 Million	99,788 Added 44.63%	323,353 $4.2 Million
Q2 2019 Aug 12, 2019	BUY	$10.67 - $15.49 $1.17 Million - $1.69 Million	109,297 Added 95.65%	223,565 $2.9 Million
Q1 2019 May 10, 2019	BUY	$15.4 - $20.39 $2,571 - $3,405	167 Added 0.15%	114,268 $1.8 Million
Q4 2018 Feb 14, 2019	SELL	$18.06 - $24.96 $253,616 - $350,513	-14,043 Reduced 10.96%	114,101 $2.3 Million
Q3 2018 Nov 14, 2018	BUY	$23.55 - $30.1 $52,657 - $67,303	2,236 Added 1.78%	128,144 $3.18 Million
Q2 2018 Aug 13, 2018	SELL	$27.45 - $33.35 $3,074 - $3,735	-112 Reduced 0.09%	125,908 $0
Q1 2018 May 14, 2018	SELL	$29.15 - $37.4 $4,664 - $5,984	-160 Reduced 0.13%	126,020 $3.88 Million
Q4 2017 Feb 13, 2018	BUY	$24.55 - $36.3 $1.18 Million - $1.75 Million	48,121 Added 61.65%	126,180 $4.51 Million
Q3 2017 Nov 02, 2017	BUY	$22.55 - $28.1 $1.76 Million - $2.19 Million	78,059	78,059 $2.15 Million

Others Institutions Holding RVNC

# of Institutions

232

Shares Held

82.1M

Call Options Held

680K

Put Options Held

896K

Black Rock Inc. New York, NY

8.57M
Shares

$22 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

5.73M
Shares

$14.7 Million
0.0% of portfolio
Franklin Resources Inc San Mateo, CA

4.78M
Shares

$12.3 Million
0.0% of portfolio
Fil LTD Hamilton, D0

4.19M
Shares

$10.8 Million
0.01% of portfolio
Alpine Associates Management Inc. Englewood Cliffs, NJ

4.16M
Shares

$10.7 Million
0.49% of portfolio

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account